Nordisk – Page 4

Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth

6 months ago talkbio0Tagged competition, Drug Industry, Eli, Eli Lilly, financial results, issues, Market, Nordisk, Obesity, Pricing, Q3 2024, Weight loss therapies

Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues

Novo Nordisk Terminates Development of Kidney Disease Drug Ocedurenone After Phase 3 Failure

6 months ago talkbio0Tagged CLARION-CKD, Drug Development, Failure (biologic function), Hypertensive disease, Kidney Diseases, Nordisk, Ocedurenone, Phase 3 trial

Novo Nordisk, ocedurenone, kidney disease, hypertension, Phase 3 trial, CLARION-CKD, drug development failure

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

6 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.

Novo Nordisk Secures $285 Million Biobucks Deal with Ascendis Pharma for Monthly GLP-1 Agonist Development

6 months ago talkbio0Tagged Agonist, Ascendis, biobucks, Drug Development, Glucagon-Like Peptide 1, Nordisk, Pharma

Novo Nordisk, Ascendis Pharma, GLP-1 agonist, biobucks deal, pharmaceutical development

Novo Nordisk’s Wegovy Shows Superior Improvement in Liver Fibrosis and MASH Resolution in Phase III ESSENCE Trial

6 months ago talkbio0Tagged Fibrosis, Liver, MASH, Nordisk, Phase III ESSENCE trial, Rezdiffra, semaglutide, Wegovy

Novo Nordisk, Wegovy, semaglutide, MASH, liver fibrosis, Phase III ESSENCE trial, Madrigal Pharmaceuticals, Rezdiffra

FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy

6 months ago talkbio0Tagged Diabetes, Drug Shortage, Nordisk, Obesity, semaglutide, United States Food and Drug Administration, Wegovy

FDA, Novo Nordisk, Ozempic, Wegovy, drug shortage, semaglutide, obesity treatment, type 2 diabetes treatment

Novo Nordisk Seeks FDA Ban on Compounded Semaglutide Formulations Amid Safety Concerns

6 months ago talkbio0Tagged concerns, Diabetes, Glucagon-Like Peptide 1, Nordisk, Pharmacy facility, Safety, semaglutide, United States Food and Drug Administration, Weight-Loss Agents

Novo Nordisk, FDA, semaglutide, compounding pharmacies, safety concerns, GLP-1 medications, weight loss drugs, diabetes treatments

Novo Nordisk’s Alhemo Nears EU Approval: A Breakthrough in Haemophilia Treatment

6 months ago talkbio0Tagged Alhemo, CHMP, concizumab, European Medicines Agency, Haemophilia A and B, inhibitors, Nordisk, Subcutaneous prophylactic treatment

Novo Nordisk, Alhemo, Haemophilia A and B, Inhibitors, European Medicines Agency (EMA), CHMP positive opinion, Subcutaneous prophylactic treatment, Concizumab